Amaç Yeni kasa invaze olmayan mesane tümörlerinin standart tedavisi mesanenin transüretral rezeksiyonu (TURM) ve intravezikal kemoterapidir. Yetersiz tümör rezeksiyonu, erken nüks ve düşük evreleme gibi hastalığın seyrini değiştirecek durumları ortaya çıkarmaktadır. Bu nedenle kasa invaze olmayan mesane tümörlerinin tedavisinde kaliteli TURM önemli bir faktördür. Gereç ve Yöntem Primer mesane tümörü nedeniyle TURM olmuş 841 hasta çalışmaya alındı. Toplam 597 hasta bu kriterlerimize uymadığı için çalışmadan çıkarıldı. Grup 1'de patoloji spesmeninde müskülaris propria (MP) görülen hastalar bulunurken; grup 2, TURM örneğinde MP görülmeyen hastalardan oluşmuştur. Hastalar; cinsiyet, tümör sayısı, patoloji spesmenindeki tümör hacmi, MP durumu, nüks durumu, nüks zamanı ve progresyon açısından değerlendirildi. Bulgular Nüks eden 92 hastanın sadece 14'ünde (%15,2) MP bulunurken geriye kalan 78 (%84,8) hasta da MP görülmemiştir (p=0,004). Grup 1'de progrese olan hasta 4 (%14,2), grup 2'de 28 (%29) hasta olarak ortaya çıkmıştır (p=0,159). Tek değişkenli analizde, tümör multiplitesi (p=0,003) ve MP yokluğu (p=0,004) rekürrens üzerine etkili bulunmuştur. Çok değişkenli analizde yine bu iki parametre nüks üzerine etkili bulunmuştur (p=0,004). Sonuç Bu çalışmada düşük dereceli evre pTa tümörlerin patoloji örneklerinde MP varlığının kaliteli bir TURM'nin göstergesi olduğu ve nüksleri önlemede iyi yapılmış TURM'nin önemine dikkat çekilmiştir.
Objective Transurethral resection (TUR) of the bladder and intravesical chemotherapy is the standard treatment option for non-muscle-invasive bladder tumors. Inadequate tumor resection results in early recurrence and staging inaccuracies, which all will change the course of the disease. High-quality TUR treatment is therefore an important factor in the treatment of non-muscle-invasive bladder tumors. In this study, we investigated the significance of detecting the presence of muscularis propria (MP) in pathology specimens of low-grade, stage pTa tumors in patients who were treated with TUR due to primary bladder tumors, with regard to recurrence, time to recurrence and progression. Materials and Methods Initially, 841 patients who were treated with TUR due to primary bladder tumors were enrolled in the study. A total of 597 patients were excluded from the study because they failed to meet the study criteria. Group 1 consisted of patients with MP detected in the pathology specimens; whereas group 2 consisted of patients whose TUR specimens did not include MP. The patients were evaluated with regard to gender, tumor number, presence or absence of MP, and recurrence status. Results MP was observed in only 14 (15.2%) of 92 patients with recurrence, but not in the remaining 78 (84.8%) (p=0.004). Progression occurred in 4(14.2%) patients of group 1 and 28 (29%) patients of group 2 (p=0.159). In univariate analysis, tumor multiplicity (p=0.003) and the absence of MP (p=0.004) were found to have effects on recurrence. In multivariate analysis, these two parameters were also found to be have effects on recurrence (p=0.004). Conclusion In this study, it was pointed out that MP presence in the pathology specimens of low-grade stage pTa tumors is an indicator of a high quality TUR and, a well-done TUR is important for the prevention of recurrence.
Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234-241.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010, International Agency for Research on Cancer: Lyon, France. http://www.iarc.fr/en/publications/eresources/cancerbases/ index.php
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J; European Association of Urology (EAU). EAU guidelines on non-muscle- invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-314.
Babjuk M. Transurethral resection of non-muscle invasive bladder cancer. Eur Urol 2009;8(Suppl):542-548.
Carmack AJ, Soloway MS. The diagnosis and staging of bladder cancer: from RBCs to TURs. Urology 2006;67(Suppl 3):3-8.
Mariappan P, Finney SM, Head E, Somani BK, Zachou A, Smith G, Mishriki SF, N'Dow J, Grigor KM; Edinburgh Urological Cancer Group. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int 2012;109:1666-1673.
Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 2001;165:808-810.
Kurth K. Natural history and prognosis of untreated and treated superficial bladder cancer. Oxford, UK: Isis Medical Media; 1997.
Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, Newling D, Bouffioux C, Sylvester RJ; EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies . Eur Urol 2002;41:523-531.
Mariappan P, Smith G, Lamb AD, Grigor KM, Tolley DA. Pattern of recurrence changes in noninvasive bladder tumours observed during 2 decades. J Urol 2007;177:867-875.
Mariappan P, Zachou A, Grigor KM; Edinburgh Uro-Oncology Group. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010;57:843-849.
Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int 2008;102:1242-1246.
Maruniak N, Takezawa K, Murphy WM. Accurate pathological staging of urothelial neoplasms requires better cystoscopic sampling. J Urol 2002;167:2404-2407.
Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer . Urology 2002;60:822-824.
Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study . J Urol 2003;170:433-437.
Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumours. J Urol 1999;162:74-76.
Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001;166:490-493.
Jesuraj MG, Harris M, Rogers A, Whiteway JE. Completeness of the first resection of bladder tumour depending on the seniority of the surgeon. Eur Urol 2008;7(Suppl 3):269.
Badalato G, Patel T, Hruby G, McKiernan J. Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect the rate of upstaging in cT1 bladder cancer? BJU Int 2010;108:1292- 1296.
Divrik T, Yildirim U, Eroğlu A, Zorlu F, Ozen H. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol 2006;175:1258-1261.
Jakse G, Algaba F, Malmstrom PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 2004;45:539-546.